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An accidental exposure of six workers to ethylene oxide (EO) provided the rationale for a biomonitoring 
and follow-up study, whose aim was to analyse protein adduct kinetics and examine the differentiation 
between accidental and environmental exposure, e.g., from tobacco smoke. For this purpose, the decrease 
in the concentration of the haemoglobin adduct N-2-hydroxyethylvaline (HEV) was followed during a 
fi ve-month period after the accident, together with N-2-cyanoethylvaline (CEV) and urinary cotinine, two 
well-established biomarkers for smoking. The follow-up study showed that EO adduct concentrations 
signifi cantly increased after a short but presumably high exposure. Initial biomonitoring revealed HEV 
levels above 500 pmol g-1 globin in all cases, with a maximum of about 2,400 pmol g-1 globin. This compares 
to a German EKA value (exposure equivalent for carcinogenic substances) for a daily 8-h-exposure to 
1 ppm EO of 90 μg L-1 blood (~3,900 pmol g-1 globin). The adduct levels dropped in accordance with the 
expected zero-order kinetics for a single exposure. After the fi ve-month observation interval, the HEV 
concentrations in blood refl ected the individual background from tobacco smoking. The results of this 
study show that even a short exposure to ethylene oxide may result in a signifi cant rise in haemoglobin 
adduct levels. Although protein adducts and their occupational-medical assessment values are considered 
for long-term exposure surveillance, they can also be used for monitoring accidental exposures. In these 
cases, the calculation of daily ‘ppm-equivalents’ may provide a means for a comparison with the existing 
assessment values.
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Ethylene oxide (EO) is an important chemical 
intermediate mainly used for the synthesis of ethylene 
glycol and its ethers, ethoxylates, ethanolamines, 
polyoles, and polyesters, or for sterilisation purposes 
(1). Its acute toxic properties comprise moderate 
irritation of the eye, the mucous membranes, and the 
upper respiratory tract with typical symptoms of 
exposure being headache, dizziness, nausea, and 
vomiting. EO is a known animal carcinogen and a 
suspected human carcinogen (2, 3). Due to its 
hazardous potential, ethylene oxide is usually handled 
and reacted in closed systems. Its use for sterilisation 
purposes, e.g., in hospitals and in the production of 
sterile disposable medical equipment, is strictly 
controlled in Germany by technical guidelines, and 
biological monitoring is recommended for health 
surveillance (4-7).
Ethylene oxide is readily absorbed either by 
inhalation or through the skin (skin notation). The 
main metabolic pathway of EO involves a hydrolysis 
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of the epoxide to yield ethylene glycol and a 
subsequent sequential oxidation to oxalate, formiate 
and carbon dioxide, or an enzymatically mediated 
conjugation to glutathione to form S-2-hydroxyethyl 
mercapturic acid (8, 9). In addition, ethylene oxide 
binds spontaneously to nucleophilic acids in proteins, 
namely to haemoglobin in blood. One of these 
covalently bound addition products, or ‘adducts’, is 
the N-terminal N-2-hydroxyethylvaline (HEV), a 
well-established biomarker for ethylene oxide 
exposure (10-12). In Germany, the Senate Commission 
for the Investigation of Health Hazards in the Work 
Area of the German Research Foundation (Deutsche 
Forschungsgemeinschaft - DFG) has established so-
called ‘exposure equivalents for carcinogenic 
substances’ (EKA), which describe the correlation 
between ethylene oxide concentrations in air and HEV 
concentrations in blood (13). A confounder for this 
biomarker is smoking, as ethylene oxide is a metabolite 
of ethene in tobacco smoke (14-16). While nonsmokers 
usually show HEV levels below 75 pmol g-1 globin, 
levels up to 550 pmol g-1 globin are observed in blood 
samples from smokers (17). One specifi c aspect in the 
interpretation of adduct biomonitoring is the fact that 
assessment and reference values are based on steady-
state concentrations. These are achieved only after a 
regular exposure for at least 120 days, which 
corresponds to the average life-span of the erythrocytes 
(18-21). Under constant exposure conditions, the 
adduct levels continue to increase during this interval 
until the equilibrium between daily increment of 
adducts and erythrocyte breakdown has been reached. 
While protein adducts are valuable markers of a long-
term integrated dose, measurement and interpretation 
of adduct levels after intermittent or single exposures 
have not yet been well established. In the context of 
isolated accidental exposures, it would also be 
interesting to see if the decline of adduct levels follows 
the expected linear function until the baseline level, 
e.g., associated mainly with regular smoking habits, 
has been reached after 120 days. In this case, an 
extrapolation of adduct concentrations, which were 
measured weeks or even months after the exposure, 
would be both possible and advantageous, as it offers 
a broader time-frame for sample collection than most 
other biomarkers.
In a study following an accidental exposure of six 
workers to ethylene oxide in a chemical plant, we 
investigated the degradation kinetics of the 
haemoglobin adduct HEV during a period of fi ve 
months. Furthermore, we calculated the additional 
exposure following the accident and developed an 
approach for the interpretation of adduct levels after 
single or short-term exposures. As the individual 
background levels from tobacco smoking are to be 
considered for HEV interpretation, urinary cotinine 
and N-2-cyanoethylvaline (a haemoglobin adduct of 
acrylonitrile in tobacco smoke) were analysed (17, 22, 
23).
MATERIALS AND METHODS
Study group and ethylene oxide exposure
Six male workers from a chemical plant were 
accidentally exposed to ethylene oxide outside the 
building. About 40 kg of liquid EO were released 
through an open valve and evaporated into the 
surroundings. While there were no specific data 
available on the concentration of EO in air, the nearby 
gas alert system was activated, thus indicating that 
several hundred ppm of EO were detected in the 
vicinity of the building. Taking into account that the 
open valve was shut after 2 to 3 min and that a mobile 
measuring station did not detect any airborne EO after 
about 15 min, the maximum exposure time of six 
workers was estimated to be 15 minutes. Immediately 
after the accidental exposure, the workers were taken 
care of in the out-patient clinic of the Occupational 
Medicine & Health Protection Department of the 
company.
Biomonitoring
Blood and urine samples were collected in the 
out-patient clinic one day after the accident and 
thereafter on a monthly basis over a five-month 
interval. Blood samples were drawn into regular 
EDTA-containing disposable syringes (Monovettes®, 
Sarstedt, Germany). The erythrocytes were separated 
from the plasma fraction by centrifugation (800 ´ g, 
5 min) and washed twice with isotonic saline (addition 
of 0.9 % sodium chloride, centrifugation, removal of 
saline) until the supernatant was colourless and clear. 
The original sample volume was then restored by 
addition of ultrapure water, while the erythrocytes 
were lysed by this procedure. To monitor exposure to 
ethylene oxide and to the tobacco smoke contaminant 
acrylonitrile, the haemoglobin adducts N-2-
hydroxyethylvaline (HEV) and N-2-cyanoethylvaline 
(CEV) were quantifi ed in these samples. The protein 
adduct analyses were carried out in an accredited and 
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certifi ed contract laboratory (Currenta, Leverkusen, 
Germany) essentially following a procedure described 
by van Sittert et al. (17). Globin was isolated from the 
haemolysates by fractionated precipitation. The dried 
protein was then subjected to the so-called ‘modifi ed 
or N-Alkyl-Edman method’ (10): the adduct-bearing 
N-terminal amino acid (HEV, CEV) was cleaved off 
of the protein chain and simultaneously derivatised 
with pentafluorophenyl isothiocyanate into a 
thiohydantoin. It was then extracted with diethyl ether, 
evaporated to dryness, and reconstituted in toluene. 
Subsequently, the samples were analysed by gas 
chromatography-mass spectrometry (GC-MS) in the 
electron impact mode.
Spot urine samples were collected in parallel to 
the blood specimens in 100 mL polystyrene containers. 
The nicotine metabolite cotinine was analysed in these 
samples in the biomonitoring laboratory of the 
Occupational Medicine & Health Protection 
Department at BASF SE, Ludwigshafen, Germany, 
according to a method described by Müller et al. (24). 
Urine samples were alkalised with sodium hydroxide 
solution and extracted with dichloromethane after the 
addition of 2-benzylpyridine as internal standard. The 
extract was then analysed by GC-MS in the electron 
impact mode using selected ion monitoring. The 
method has been tested and certifi ed within several 
round-robin tests of the German External Quality 
Assessment Scheme (G-EQUAS, c/o Institute of 
Occupational, Social and Environmental Medicine of 
the University of Erlangen-Nuremberg). To correct 
for diuretic variance, urinary creatinine was analysed 
by an HPLC-UV method (25) in the BASF laboratory. 
This parameter was also successfully certifi ed within 
the G-EQUAS program.
Data processing and calculations
All calculations were carried out with either the 
Microsoft® Offi ce Excel 2003 software package or 
with IBM® SPSS® Statistics 19.0.
RESULTS
Four of the six workers exposed to ethylene oxide 
reported moderate acute effects: mild irritation of the 
mucous membranes and the upper respiratory tract, 
dizziness, shortness of breath, cough, and headache. 
Lung function testing of one worker revealed a slightly 
reduced peak fl ow. Two workers with pulmonary 
symptoms received intravenous corticoids for lung 
oedema prevention according to the established 
medical guidelines (26) and stayed in a clinic overnight 
for observation. Four days after the accidental 
exposure, two workers still reported general weariness 
and one of them felt a sunburn-like itchy feeling on 
some parts of his skin. All observed effects had 
completely resolved by the time the fi rst follow-up 
biomonitoring investigation was carried out, four 
weeks after the accident.
As individual smoking habits are an important 
factor for further interpretation of the adduct levels of 
exposure to ethylene oxide, two biomarkers of tobacco 
smoke, urinary cotinine and haemoglobin adduct CEV, 
were analysed in order to confi rm the self-reported 
smoker status of the employees (Table 1). Cotinine 
biomonitoring results for all self-reported smokers 
(study participants 1, 2, 3, 5, and 6) were always high 
above the reference values (95th percentiles) of 
16 μg g-1 creatinine for never-smokers and 53 μg g-1 
Table 1  Results of N-2-cyanoethylvaline and cotinine analyses (-- no sample collected, n.d. not detectable, S smoker, NS 
nonsmoker)
Worker Biomarker Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Average
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creat inine for  ex-smokers  (Third German 
Environmental Survey) (27). Many samples showed 
cotinine levels above 1,000 μg g-1 creatinine, these 
results being well in the range of typical smokers. The 
German Federal Environment Agency reports a 
cotinine median of 998 μg g-1 creatinine and a 95th 
percentile of 3,340 μg g-1 creatinine for a representative 
sample of smokers (n=1,605) (27). The individual 
smoking status was further confi rmed by the CEV 
analyses: all adduct levels were above 50 pmol g-1 
globin, whereas nonsmokers normally show CEV 
levels below 10 pmol g-1 globin (13). Only one worker 
(study participant 4) declared himself a nonsmoker 
and biomonitoring results confi rmed this: CEV was 
not detectable in blood samples of this employee and 
the cotinine levels were between 10 μg g-1 and 14 μg
g-1 creatinine. Both tobacco smoke related biomarkers 
showed a distinct intra-individual variation during the 
study interval, with a larger variability of the short-
term biomarker cotinine (average: 53 %) as compared 
to the protein adduct CEV (average: 30 %).
The results of the initial and follow-up biomonitoring 
of HEV in the six workers are summarised in Table 
2. The adduct levels observed one day after the 
accidental exposure (four days in one case) ranged 
between 522 pmol g-1 and 2,396 pmol g-1. Every 
worker provided fi ve more samples in the following 
four months (one sampling time was missed by study 
participant 1), however not always strictly according 
to the scheduled 30-day intervals. Nevertheless, the 
follow-up data showed the expected decline in 
individual HEV concentrations until the sixth 
sampling, which took place after 162 days (166 days 
in one case). The smokers still showed HEV levels in 
a range between 151 pmol g-1 and 276 pmol g-1 globin 
at the end of the study; this is consistent with typical 
smoker values as reported, for example, by van Sittert 
et al. (17), Bader et al. (16) and Schettgen et al. (22). 
This also confi rms the results of biomonitoring for 
urinary cotinine and CEV. In contrast, the nonsmoking 
employee revealed an HEV level of only 30 pmol g-1 
globin. According to Törnqvist et al. (28), background 
levels of HEV in nonsmokers are probably associated 
with ethene production by intestinal bacteria. Typical 
HEV levels in nonsmokers are below 50 pmol g-1 
globin (16, 17, 22).
Due to the average life-span of human erythrocytes 
of about 120 days, the fi nal HEV concentration of 
every individual more than 160 days after the 
accidental exposure was regarded as the tobacco 
smoke and intestinal ethene related background. This 
value was therefore subtracted from the initially 
measured adduct concentration in order to calculate 
the impact of the additional accidental exposure on 
HEV levels (Table 3). According to the German EKA 
values for ethylene oxide, a daily exposure to 1 ppm 
(1830 μg m-3) EO corresponds to an HEV level of 
approximately 3,900 pmol g-1 globin under steady-
state conditions (13), which in turn refl ects the average 
exposure of 60 working days (12). Therefore, an 
increment of 3,900/60=65 pmol g-1 per 8-h-exposure 
day can be calculated and used to derive ‘ppm-
equivalents’ from the adduct concentrations related to 
accidental exposure. Following this approach, the 
adduct levels of the exposed workers correspond to 5 
to 36 ‘ppm-equivalents’.
To analyse adduct kinetics, the initial HEV results 
were individually adjusted to 100 % after subtraction 
of the respective background values (Figure 1). A 
cubic fi t (R2=0.950, p<0.001) was applied in this case 
Table 2 Results of N-2-hydroxyethylvaline adduct analyses (-- no sample collected)
Worker Biomarker Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6
1
days post-exposure
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to visualise the reduction of adduct concentrations and 
its confi dence interval. It is noteworthy that after more 
than 120 days the HEV values were still higher than 
the fi nal background values (>160 days). This was 
also the case with the nonsmoking study participant, 
thus pointing to a fraction of exposed erythrocytes 
with a longer than average life-span. According to the 
assumption of a constant adduct decline following 
zero-order kinetics during the fi rst 120 days (12, 21), 
all adjusted HEV results between initial biomonitoring 
and 130 days post-exposure were subjected to a linear 
regression analysis (Figure 2). The resulting linear fi t 
was y (% of the initial HEV concentration after a single 
exposure) = - 0.81 (0.68 to 0.94) ´ (days post-
exposure) + 95 (86 to 104) (with R2=0.865, p<0.001, 
numbers in brackets = 95 % confi dence intervals). 
According to this equation, the concentration of HEV 
after one-time exposure decreases constantly at a rate 
of 0.81 % of the initial value per day until the 
background level is reached after 95/0.81=117 days 
(or 123 days, in case only the slope of the curve is 
considered).
DISCUSSION
Six workers of a chemical plant were exposed 
during a period of approximately 15 min to vaporous 
ethylene oxide. Although no data on the exposure 
intensity were available, a rough estimate was made 
that about 40 kg of liquid EO were released and 
vapourised rapidly. Ethylene oxide is heavier than air 
and its distribution within a radius of 50 m and up to 
a height of 5 m (~39,270 m3) would result in a mean 
concentration of about 1,000 mg m-3 or 500 ppm, 
Table 3  Initial, tobacco smoke and accidental exposure related HEV concentrations and calculation of ‘ppm-equivalents’ 
(ppm-equivalents calculated by dividing the additional accidental exposure by the daily increment of 65 pmol 












1 2,396 30 2,366 36
2 1,961 164 1,797 30
3 970 151 819 13
4 771 233 538 8
5 658 276 382 6
6 522 207 315 5
Figure 2  Linear regression fi t of ethylene oxide adducts during 
the fi rst 130 days post-exposure (y = -0.81 × (days) 
+ 95, R2 = 0.865, p < 0.001; HEV adjusted for 
background exposure and related to initial adduct 
concentration)
Figure 1  Time-course of ethylene oxide adducts (cubic fi t and 
95 % confi dence intervals, y = -1.647 x + 0.009 x2 
– 0.00002 x3 + 106, R2 = 0.950, p < 0.001; HEV 
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respectively. This estimated concentration is far above 
the previous German Technical Guideline Concentration 
(TRK) for EO of 1 ppm and would explain why the 
gas alert system in the vicinity of the leak was 
triggered. Also, the irritative effects and pulmonary 
symptoms experienced by four workers are consistent 
with a short but high exposure to ethylene oxide (2).
First of all, ethylene oxide adducts were monitored 
in order to identify exposed workers and to provide a 
quantitative measure for the exposure intensity. As the 
initially measured adduct concentrations were 
considered to be fairly high in relation to the short 
exposure time, follow-up biomonitoring was 
implemented and adduct kinetics was studied to 
confi rm the association of adduct concentrations with 
the accidental exposure. It was assumed that additional 
adduct levels would attenuate in a linear fashion down 
to background levels within 120 days, in accordance 
with zero-order kinetics (12, 21, 29). While the 
constant decrease of haemoglobin adducts after a 
single, or accidental, exposure can be estimated on 
the basis of the known life-span of erythrocytes, 
reports on this aspect from human in vivo studies are 
scarce (30, 31). In theory, a single exposure to ethylene 
oxide during one work shift leads to the formation of 
covalently bound and chemically stable adducts to 
erythrocyte haemoglobin in the blood. The total 
erythrocyte population in humans at a given point in 
time comprises an equally distributed number of cells 
between one day and a maximum of 120 days of age, 
which is the typical life-span of an erythrocyte. After 
the exposure event, the adducts are removed together 
with the haemoglobin and erythrocytes at a theoretical 
rate of 1/120x100=0.83 percent per day until, after 
about 120 days, all adducts associated with the single 
exposure have been eliminated. In the case of ethylene 
oxide adducts, nonsmokers as well as smokers reveal 
a distinct adduct background due to endogenously 
formed ethene from intestinal bacteria or from ethene 
in tobacco smoke, respectively (10, 28, 32). Follow-up 
biomonitoring in this study has provided new in vivo 
human data to support the above-mentioned 
toxicokinetic considerations. As can be seen in the 
Figures 1 and 2, the elimination curve can reasonably 
be described with a linear fi t during the fi rst three 
post-exposure months, while the attenuation curve 
seems to level off near the end of and beyond the 120-
day interval. As the erythrocytes’ life-span may vary 
to a certain degree, the asymptotically extended curve 
may be due to a fraction of older erythrocytes with 
haemoglobin adducts from the accidental exposure. 
Nevertheless, the linear decline during the fi rst post-
exposure months points to an almost complete 
elimination after about 120 days (range: 101 to 140 
days), which is in very good accordance with expected 
kinetics. In an earlier study by Bader and Wrbitzky 
(31), a somewhat longer average elimination phase of 
148 days was observed for acrylonitrile adducts. 
However, the database in that investigation was 
smaller than in the study presented here, as it 
comprised only samples from four individuals and 
three sampling times during the 120-day interval.
In this study, urinary cotinine and the acrylonitrile 
adduct CEV were analysed alongside with the ethylene 
oxide adducts. Both biomarkers were monitored in 
order to confi rm the self-reported smoker status, but 
also to provide a measure for constant or changing 
smoking behaviours of the study participants. While 
both biomarkers showed a relatively large variability, 
the results can be interpreted in the way that individual 
smoking habits of the participants did not change 
signifi cantly during the study interval. Therefore, the 
results of the last HEV analyses after about 160 days 
can reasonably be regarded as the individual adduct 
background values of the study participants. In one 
case (worker no. 1), the result of one HEV determination 
was available from a general survey three months 
before the accidental exposure. This earlier adduct 
level was 224 pmol g-1 globin as compared to the 
164 pmol g-1 globin found 166 days after the accidental 
exposure. The variation of the mean value of these 
results (30 pmol g-1 globin=15 % of the 194 pmol g-1 
globin mean value) is within the range of the analytical 
uncertainty of the adduct method. It seems reasonable 
to assume that both values refl ect the same adduct 
background associated with cigarette smoking and the 
endogenous exposure.
Another important aspect of linearity of the adduct 
attenuation curve is that it allows for a back-calculation 
of the initial post-accidental adduct levels from 
samples collected several days or weeks after the 
exposure. The validity of this approach relies, 
however, on the exposure intensity. As the analytical 
method has an imprecision of about 12 % (17), the 
additional adduct formation related to exposure should 
be at least higher than ~25 % of the background value, 
otherwise it may go undetected. Therefore, it seems 
advisable in the case of an accidental exposure to 
collect at least two samples, one in connection with 
the exposure and one after the 120-day interval in 
order to distinguish between additional and background 
exposure. If the fi rst sample is signifi cantly higher 
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than the background value, considering the analytical 
imprecision, an extrapolation to the initial adduct 
concentration is warranted. Although increased adduct 
levels may be observed still weeks and even months 
after the exposure, in particular when the exposure 
was high, the collection of blood should be carried out 
as promptly as feasible.
A particularly diffi cult and yet untackled question 
is the assessment of adduct concentrations after single 
or accidental exposures. Current assessment values 
for adducts such as the EKA of the German DFG are 
based on the assumption of a steady-state condition, 
which is reached only after at least 120 days of 
exposure. Provided, e.g., that an individual is exposed 
to a similar ethylene oxide concentration for 8 hours 
a day, the adduct levels will accumulate and rise with 
a certain daily increment which is refl ective of the 
daily absorbed dose. However, older erythrocytes are 
also removed constantly from the blood stream. 
Therefore, a steady-state is achieved only after one 
life-span of the erythrocytes (120 days) has elapsed, 
and the corresponding adduct level reflects the 
cumulative dose of 60 exposure days, or 60 daily 
increments (12, 21). The German EKA value for a 
daily exposure to 1 ppm ethylene oxide is 90 μg L-1, 
or a rounded 3,900 pmol g-1 globin (13). Therefore, a 
daily (8 h exposure) increment or ‘ppm-equivalent’ of 
3,900/60=65 pmol g-1 globin can be calculated and 
used for the assessment of single or accidental ethylene 
oxide exposures.
In the current study, the initial adduct levels are 
equivalent to an 8-h-exposure of workers to 5 to 36 
‘ppm-equivalents’. Considering the 15-min exposure 
interval (1/32 of an 8-h-shift), these equivalents 
correspond to a short-term exposure of 160 ppm to 
1152 ppm (300 mg m-3 to 2000 mg m-3) a value well 
in line with the estimated EO concentration as 
discussed above on the basis of the released material, 
and also in accordance with the activation of the 
facility’s gas alert system. Additionally, acute toxic 
effects of ethylene oxide as described by the workers 
are plausible for a short-term exposure to several 
hundred ppm EO.
In conclusion, the biomonitoring follow-up study 
has confi rmed theoretical considerations on adduct 
kinetics in humans and enabled the evaluation of 
‘ppm-equivalents’ for the assessment of short-term 
exposure incidents. This approach may further assist 
in a more widespread and extended application of 
protein adduct analysis for the monitoring of exposure 
to carcinogenic substances, including short-term 
accidental exposures, with the most significant 
practical advantage of offering a broad time frame for 
sampling.
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Sažetak
ANALIZA PROTEINSKIH ADUKATA KAO BIOMARKERA KRATKOTRAJNE IZLOŽENOSTI 
ETILEN OKSIDU I REZULTATI BIOMONITORINGA
U radu su prikazani rezultati biomonitoringa provedenog neposredno nakon akcidentalnog izlaganja 
šestorice radnika etilen oksidu i studije praćenja (follow up) provedene u cilju procjene kinetike razgradnje 
proteinskih adukata i utvrđivanja razlika nakon kratkotrajne izloženosti i izlaganja čimbenicima iz okoliša 
kao što je duhanski dim. U tu smo svrhu tijekom petomjesečnoga razdoblja nakon nezgode pratili smanjenje 
koncentracije hemoglobinskog adukta N-2-hidroksietilvalina usporedo s mjerenjem razina N-2-
cijanoetilvalina i kotinina u mokraći, koji su pouzdani biomarkeri za dokazivanje pušenja duhana. Studija 
praćenja je pokazala da su koncentracije adukata etilen oksida značajno porasle nakon kratkotrajnoga 
izlaganja visokoj razini etilen oksida. U početnom biomonitoringu svih radnika izmjerene su razine N-2-
hidroksietilvalina iznad 500 pmol g-1 globina, s maksimalnom vrijednošću od oko 2400 pmol g-1 globina. 
Ti su podaci usporedivi s vrijednostima njemačkih normi ekvivalenata izlaganja kancerogenim tvarima 
(EKA) od 90 μg L-1 krvi (~3900 pmol g-1 globina) kroz osmosatno dnevno izlaganje koncentraciji od 1 
ppm etilen oksida. Razine adukata smanjile su se u skladu s očekivanom kinetikom nultoga reda za 
jednokratno izlaganje. Koncentracije N-2-hidroksietilvalina izmjerene u krvi radnika nakon petomjesečnoga 
praćenja mogu se povezati s njihovim osobnim pušačkim navikama. Rezultati toga istraživanja pokazuju 
da čak i kratkotrajna izloženost etilen oksidu može znatno povisiti razine adukata hemoglobina. Premda 
se u zdravstvenom nadzoru u okviru medicine rada proteinski adukti i njihove vrijednosti razmatraju u 
procjeni dugotrajnoga izlaganja, oni se mogu koristiti i za praćenje akcidentalnih izlaganja. U tim 
slučajevima izračun dnevnih vrijednosti (tzv. ppm-ekvivalenata) može poslužiti za usporedbu s postojećim 
procijenjenim vrijednostima.
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